Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus

Table 1

Linear mixed-effects model of anti-dsDNA with the clinical SELENA-SLEDAI and physician’s global assessment (PGA). Slope estimates (SEM) with value and marginal R² are given for each of the anti-dsDNA tested. For example, a one-log decrease in QUANTA Flash anti-dsDNA was associated with a 1.08-unit decrease in clinical SELENA-SLEDAI.

Assay	Clinical SELENA-SLEDAI	PGA
QF dsDNA	1.08 ± 0.24; ()	0.08 ± 0.03; ()
HA anti-dsDNA	0.77 ± 0.28; ()	0.03 ± 0.03; ()
QL anti-dsDNA	0.69 ± 0.4; ()	−0.05 ± 0.05; ()
CLIFT anti-dsDNA	0.49 ± 0.3; ()	0.07 ± 0.05; ()

QF: QUANTA Flash; HA: high affinity; QL: QUANTA Lite; CLIFT: Crithidia luciliae indirect immunofluorescence test.